324 related articles for article (PubMed ID: 15689582)
1. 131I-tositumomab therapy as initial treatment for follicular lymphoma.
Kaminski MS; Tuck M; Estes J; Kolstad A; Ross CW; Zasadny K; Regan D; Kison P; Fisher S; Kroll S; Wahl RL
N Engl J Med; 2005 Feb; 352(5):441-9. PubMed ID: 15689582
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
[TBL] [Abstract][Full Text] [Related]
3. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP
J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031
[TBL] [Abstract][Full Text] [Related]
5. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
Leonard JP; Coleman M; Kostakoglu L; Chadburn A; Cesarman E; Furman RR; Schuster MW; Niesvizky R; Muss D; Fiore J; Kroll S; Tidmarsh G; Vallabhajosula S; Goldsmith SJ
J Clin Oncol; 2005 Aug; 23(24):5696-704. PubMed ID: 16110029
[TBL] [Abstract][Full Text] [Related]
6. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
[TBL] [Abstract][Full Text] [Related]
7. The radioisotope contributes significantly to the activity of radioimmunotherapy.
Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
[TBL] [Abstract][Full Text] [Related]
8. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
[TBL] [Abstract][Full Text] [Related]
9. Development of 131I-tositumomab.
Lewington V
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A
J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764
[TBL] [Abstract][Full Text] [Related]
11. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
Smith K; Byer G; Morris CG; Kirwan JM; Lightsey J; Mendenhall NP; Hoppe BS; Lynch J; Olivier K
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1122-7. PubMed ID: 21570217
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
Horning SJ; Younes A; Jain V; Kroll S; Lucas J; Podoloff D; Goris M
J Clin Oncol; 2005 Feb; 23(4):712-9. PubMed ID: 15613695
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
Kaminski MS; Zasadny KR; Francis IR; Fenner MC; Ross CW; Milik AW; Estes J; Tuck M; Regan D; Fisher S; Glenn SD; Wahl RL
J Clin Oncol; 1996 Jul; 14(7):1974-81. PubMed ID: 8683227
[TBL] [Abstract][Full Text] [Related]
15. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
Davies AJ; Rohatiner AZ; Howell S; Britton KE; Owens SE; Micallef IN; Deakin DP; Carrington BM; Lawrance JA; Vinnicombe S; Mather SJ; Clayton J; Foley R; Jan H; Kroll S; Harris M; Amess J; Norton AJ; Lister TA; Radford JA
J Clin Oncol; 2004 Apr; 22(8):1469-79. PubMed ID: 15084620
[TBL] [Abstract][Full Text] [Related]
16. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
Friedberg JW; Fisher RI
Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
[TBL] [Abstract][Full Text] [Related]
17. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
Wahl RL
J Nucl Med; 2005 Jan; 46 Suppl 1():128S-40S. PubMed ID: 15653661
[TBL] [Abstract][Full Text] [Related]
18. Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist's view.
Davies AJ
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):305-16. PubMed ID: 15640794
[TBL] [Abstract][Full Text] [Related]
19. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Bennett JM; Kaminski MS; Leonard JP; Vose JM; Zelenetz AD; Knox SJ; Horning S; Press OW; Radford JA; Kroll SM; Capizzi RL
Blood; 2005 Jun; 105(12):4576-82. PubMed ID: 15731177
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
